共 145 条
[11]
Moir D(2017)PD-1, PD-L1 (B7-H1) and tumor-site immune modulation therapy: the historical perspective J Hematol Oncol 10 34-506
[12]
Hancock B(2017)Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy J Hematol Oncol 10 174-846
[13]
McMillan A(2002)Expression of a mutated form of the p85alpha regulatory subunit of phosphatidylinositol 3-kinase in a Hodgkin’s lymphoma-derived cell line (CO) Leukemia 16 19-68
[14]
Schmitz N(2005)Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin’s lymphoma cells through a mechanism involving Akt kinase and mTOR J Pathol 205 498-5173
[15]
Pfistner B(2005)HLXB9 activates IL6 in Hodgkin lymphoma cell lines and is regulated by PI3 K signalling involving E2F3 Leukemia 19 841-1414
[16]
Sextro M(2010)Tissue-microarray based immunohistochemical analysis of survival pathways in nodular sclerosing classical Hodgkin lymphoma as compared with non-Hodgkin’s lymphoma Int J Clin Exp Med 3 55-1807
[17]
Sieber M(2006)Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies Clin Cancer Res 12 5165-10
[18]
Carella AM(2010)Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia J Clin Oncol 28 1408-854
[19]
Haenel M(2005)A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein beta and NF-κB activity in Hodgkin and anaplastic large cell lymphomas Blood 106 1801-1243
[20]
Gutierrez-Delgado F(2010)A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma Am J Hematol 85 26-3068